Stock Analysis

3 Stocks Estimated To Be Trading Up To 47% Below Intrinsic Value

Published

As global markets navigate a period of mixed performance, with the Nasdaq reaching new heights while other major indexes face declines, investors are keenly observing the economic indicators such as inflation rates and central bank policies. Amidst this complex environment, identifying undervalued stocks becomes increasingly appealing for those looking to capitalize on potential discrepancies between market prices and intrinsic values. A good stock in this context is one that demonstrates strong fundamentals yet trades below its estimated worth, offering potential value opportunities in an uncertain market landscape.

Top 10 Undervalued Stocks Based On Cash Flows

NameCurrent PriceFair Value (Est)Discount (Est)
Strike CompanyLimited (TSE:6196)¥3645.00¥7281.6549.9%
Sudarshan Chemical Industries (BSE:506655)₹1129.35₹2250.9549.8%
Wuhan Keqian BiologyLtd (SHSE:688526)CN¥14.62CN¥29.0949.7%
Lindab International (OM:LIAB)SEK225.40SEK450.7550%
Decisive Dividend (TSXV:DE)CA$5.93CA$11.8449.9%
GlobalData (AIM:DATA)£1.875£3.7550%
Western Alliance Bancorporation (NYSE:WAL)US$82.86US$165.3049.9%
HealthEquity (NasdaqGS:HQY)US$94.76US$189.2249.9%
Charter Hall Group (ASX:CHC)A$14.37A$28.5849.7%
Hanall Biopharma (KOSE:A009420)₩32650.00₩65043.1549.8%

Click here to see the full list of 911 stocks from our Undervalued Stocks Based On Cash Flows screener.

Let's uncover some gems from our specialized screener.

Ercros (BME:ECR)

Overview: Ercros, S.A. is a Spanish company that manufactures and sells basic chemicals, intermediate chemicals, and pharmaceuticals, with a market cap of €324.60 million.

Operations: The company generates revenue from three main segments: Pharmaceuticals (€63.57 million), Chlorine Derivatives (€375.76 million), and Intermediate Chemicals (€193.57 million).

Estimated Discount To Fair Value: 14.4%

Ercros, S.A. is trading at €3.55, below its estimated fair value of €4.15, indicating it may be undervalued based on cash flows. Despite a net loss of €7.8 million for the first nine months of 2024 and a decline in revenue to €533.61 million, earnings are forecast to grow significantly at 48.52% annually over the next three years, outpacing the Spanish market's growth rate. However, return on equity remains low and dividends are unstable.

BME:ECR Discounted Cash Flow as at Dec 2024

izertis (BME:IZER)

Overview: Izertis, S.A. offers technological consultancy services both in Spain and internationally, with a market cap of €263.63 million.

Operations: The company's revenue is primarily generated from its Technologies and Information (IT) segment, amounting to €124.33 million.

Estimated Discount To Fair Value: 11.8%

Izertis, S.A. is trading at €9.82, slightly below its estimated fair value of €11.14, suggesting it is undervalued based on cash flows. Despite a decline in net income to €1.32 million for the first half of 2024, earnings are expected to grow significantly at 40.86% annually over the next three years, surpassing the Spanish market's growth rate. However, interest payments are not well covered by earnings and shareholders have faced dilution recently.

BME:IZER Discounted Cash Flow as at Dec 2024

JYP Entertainment (KOSDAQ:A035900)

Overview: JYP Entertainment Corporation is a South Korean entertainment company with international operations, and it has a market cap of approximately ₩2.40 trillion.

Operations: The company's revenue is primarily derived from Entertainment at ₩470.40 billion, followed by Distribution and Sales at ₩78.85 billion, and Music Publishing at ₩10.51 billion.

Estimated Discount To Fair Value: 47%

JYP Entertainment is trading at ₩72,300, significantly below its estimated fair value of ₩136,385.16, highlighting potential undervaluation based on cash flows. Despite a decrease in net profit margin from 21.9% to 13.5%, the company's earnings and revenue are forecasted to grow annually by 19% and 11.2%, respectively—outpacing the Korean market averages. However, revenue growth remains moderate compared to high-growth benchmarks.

KOSDAQ:A035900 Discounted Cash Flow as at Dec 2024

Key Takeaways

Contemplating Other Strategies?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Valuation is complex, but we're here to simplify it.

Discover if izertis might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com